lapatinib has been researched along with Lymph Node Metastasis in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 15 (93.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anne Zujewski, J; Azim, HA; De Azambuja, E; Gingras, I; Gnant, M; Gralow, JR; Harris, L; Holmes, E; Inbar, M; Izquierdo, M; Moreno-Aspitia, A; Naume, B; Nguyen, DH; Piccart, MJ; Tomasello, G; Wolff, AC | 1 |
| Chu, E | 1 |
| Jiao, S; Ju, Y; Sun, S | 1 |
| Chang, JC; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Mayer, IA; Nanda, R; Osborne, CK; Pavlick, AC; Rimawi, MF; Rodriguez, AA; Schiff, R; Wang, T | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yoneyama, S | 1 |
| Brain, E; Briggs, K; Caglevic, C; DeSilvio, M; Janni, W; Karaszewska, B; Mahood, K; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM | 1 |
| Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D | 1 |
| Bilici, A; Gumus, M; Kefeli, AU; Kefeli, U; Seker, M; Ustaalioglu, BB; Yildirim, ME | 1 |
| Canto, M; Ding, P; Dunbar, KB; Eshleman, JR; Feldmann, G; Goff, D; Haffner, MC; Heckrodt, TJ; Hector, A; Holland, SJ; Hong, SM; Karikari, C; Maitra, A; Marimuthu, A; Meeker, AK; Montgomery, EA; Nelkin, BD; Pandey, A; Riggins, GJ; Roa, JC; Singh, R; Wang, JS; Yu, J; Zhang, J | 1 |
| Egerton, N | 1 |
| Chiuri, VE; De Laurentiis, M; Giampaglia, M; Lorusso, V; Silvestris, N; Tinelli, A | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T | 1 |
| Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ | 1 |
2 review(s) available for lapatinib and Lymph Node Metastasis
| Article | Year |
|---|---|
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2010 |
Lapatinib in breast cancer: clinical experiences and future perspectives.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Forecasting; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
8 trial(s) available for lapatinib and Lymph Node Metastasis
| Article | Year |
|---|---|
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
Topics: Antineoplastic Agents; Axilla; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lapatinib; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab; Tumor Burden | 2017 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
Ongoing Clinical Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Peptide Fragments; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2016 |
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms | 2008 |
6 other study(ies) available for lapatinib and Lymph Node Metastasis
| Article | Year |
|---|---|
How I treat chemorefractory metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Neoplasm Staging; Nivolumab; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thymine; Trastuzumab; Trifluridine; Uracil; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Prolonged overall survival in metastatic gastric cancer treated with ipilimumab and lapatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Humans; Ipilimumab; Lapatinib; Lymphatic Metastasis; Male; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Stomach Neoplasms; Treatment Outcome | 2018 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2013 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Quinazolines | 2011 |
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Axl Receptor Tyrosine Kinase; Barrett Esophagus; Benzocycloheptenes; Cell Movement; Esophageal Neoplasms; Female; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lapatinib; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; ral GTP-Binding Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Survival Rate; Triazoles | 2010 |
Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab.
Topics: Abdominal Pain; Adenocarcinoma, Papillary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Immunohistochemistry; Lapatinib; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2011 |